---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000014"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:42:46.638456+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM

## Summary
- As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.
- IMM-1-104 with mFFX generally well tolerated; 3 partial responders and 1 stable disease patient remain on treatment.
- Raised net proceeds of $13.7M in January 2025 through at-the-market equity offering program.

## SEC filing metadata
- accession: 0001790340-25-000014
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/0001790340-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/imrx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000014
- JSON: https://secwatch.observer/filing/0001790340-25-000014.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.